Industry

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Based on DESTINY-Lung02 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reported a confirmed objective response rate of 57.7% in patients with HER2 mutant disease TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable … [Read more…]

Silence Therapeutics Announces Pricing of Underwritten Offering

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten offering of 5,950,000 American Depositary Shares (“ADSs”), each representing three ordinary shares, at a price … [Read more…]

Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements

BRAMPTON, Ontario–(BUSINESS WIRE)–Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate matter over the specified requirements. This recall is being conducted … [Read more…]

U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #CourtofAppeals–Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic. “We are pleased that the U.S. Court of Appeals has once again ruled in … [Read more…]

LifeWorks reports Q2 2022 results, court approval and key regulatory approvals for transaction with TELUS and a conditional agreement to acquire Benestar

Not for distribution to U.S. news wire services or for dissemination in the U.S. TORONTO–(BUSINESS WIRE)–LifeWorks Inc. (the “Company” or “LifeWorks”) (TSX: LWRK) today reported its financial results for the three and six-month period ended June 30, 2022 (all amounts are in Canadian dollars, unless noted otherwise). LifeWorks acquisition by TELUS Binding agreement for C$2.9 … [Read more…]

TELUS and LifeWorks receive court approval and key regulatory approvals for proposed acquisition

Not for distribution to U.S. news wire services or for dissemination in the U.S. VANCOUVER, British Columbia & TORONTO–(BUSINESS WIRE)–TELUS Corporation (“TELUS”) (TSX: T; NYSE: TU) and LifeWorks Inc. (“LifeWorks”) (TSX: LWRK) today announced that the Ontario Superior Court of Justice (Commercial List) has granted its final order (the “Court Approval”) approving the plan of … [Read more…]

Henry Schein Announces the Passing of Board Member E. Dianne Rekow

MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) announced the passing today of E. Dianne Rekow, DDS, Ph.D., a member of the Company’s Board of Directors since 2014 and a leader in the development of digital dentistry. “Dianne was an extraordinary board member and an internationally known authority on aesthetic and restorative dentistry as well as … [Read more…]

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VTGN #mentalhealth—VistaGen Therapeutics, Inc. (Nasdaq: VTGN), … [Read more…]

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update

Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring … [Read more…]

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022 On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of … [Read more…]